Sign In
Buy R
$260.38
+2.32 (+0.90%)
At Close: Jun 03, 2026
Mace(R) Security International, Inc. Announces Completion of Going Private Merger with W Electric Intermediate Holdings, LLC
05:15pm, Friday, 06'th Dec 2024
CLEVELAND, OH / ACCESSWIRE / December 6, 2024 / Mace Security International (OTCQB:MACE) (the "Company") announces the completion of the merger (the "Merger") contemplated by the Agreement and Plan of
Mace(R) Security International, Inc. Announces Stockholder Approval of Merger with W Electric Intermediate Holdings, LLC
10:30am, Thursday, 05'th Dec 2024
CLEVELAND, OH / ACCESSWIRE / December 5, 2024 / Mace Security International (OTCQB:MACE) (the "Company) announces the results of the Special Meeting of its stockholders held on December 3, 2024. At th
Theralase(R) Launches New Clinical Study Site in Canada
07:00am, Thursday, 05'th Dec 2024
St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / ACCESSWIRE
New Highs for Dow Transports: Top 3 Stocks Driving the Surge
08:30am, Wednesday, 04'th Dec 2024
The Dow Jones Transportation Average rose more than 8.4% in November to set a new high. Most components saw gains, with only two moving lower.
Ryder Sets New Giving Record With $1.150 Million Donation to United Way
06:55am, Tuesday, 03'rd Dec 2024
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) announces the company's annual United Way workplace campaign contributions for 2024 total $1.150 million—setting a record in the company's more t
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
04:00pm, Monday, 02'nd Dec 2024
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - Dece
Theralase(R) Release's 3Q2024 Financial Statements
05:05pm, Wednesday, 27'th Nov 2024
TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the rese
Here's Why Investors Should Retain Ryder Stock Right Now
10:40am, Wednesday, 27'th Nov 2024
R's robust initiatives toward sustainability are praiseworthy. Shareholder-friendly approach too bodes well for R.
Ryder CEO to Address Goldman Sachs Industrials & Materials Conference
06:55am, Tuesday, 26'th Nov 2024
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chairman & CEO Robert Sanchez will present a company update at the Goldman Sachs Industrials & Materials Conference 2024. Who: R
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company in the
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
08:15am, Thursday, 21'st Nov 2024
Brisbane, Queensland, Australia--(Newsfile Corp. - November 21, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the launch of SUPER
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% r
GMG Reaches Market Commercialisation Milestone on Energy Savings Coating THERMAL-XR(R)
08:00am, Tuesday, 19'th Nov 2024
Brisbane, Queensland, Australia--(Newsfile Corp. - November 19, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide a business update on
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in pr
Theralase(R) Closes Non-Brokered Private Placement
07:00am, Friday, 15'th Nov 2024
TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
